John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management


Manage episode 318118139 series 2942795
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

255 episodes